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CASE REPORT
A 50-year-old female previous smoker presented with a 
chief complaint of hemoptysis. A computed tomography 
(CT) scan of the chest with and without contrast revealed 
a lobulated 1.6 cm mass in the left upper lobe bronchus. 
Fluorodeoxyglucose-positron emission tomography CT 
imaging showed no other evidence of systemic disease and 
her Eastern Cooperative Oncology Group performance status 
was 0. Bronchoscopy with biopsy revealed that the mass con-
sisted of atypical spindle cells. The patient then underwent 
bronchoscopy for cauterization of the bleeding tumor and 
thoracoscopic left upper lobe sleeve lobectomy with lymph 
node dissection. Histopathology of the tumor was consistent 
with inflammatory myofibroblastic tumor (IMT), measuring 
2.5 cm (Fig. 1). Immunohistochemistry was strongly positive 
for vimentin and focally positive for smooth muscle actin. 
Cytokeratin AE1/3, S-100, desmin P63, ALK-1, CD34, and 
BCL-2 were negative. No ALK or ROS1 gene rearrangements 
were observed. After 3 months, CT angiography with three-
dimensional virtual bronchoscopic reconstructions showed 
no bronchial stricture, intraluminal disease or extraluminal 
pathology. Repeated surveillance bronchoscopy, performed 
7 months postoperatively, revealed a 2 mm nodule located 
1 cm distal to the carina (Fig. 2A). Pathological analysis 
confirmed recurrent IMT morphologically identical to the 
original tumor. Immunohistochemical staining and ALK 
translocation analysis were not repeated. CT of the chest 
with and without contrast revealed postsurgical changes in 
the left lung with some irregularity and lobulation of the 
left main stem bronchus but without any evidence of local 
recurrence or metastasis. Treatment options offered to her 
at another institution were left complete pneumonectomy or 
local ablative therapy. The latter, however, was concerning 
for potentially accelerating recurrence from thermal injury.1 
The patient thus agreed to treatment with celecoxib 200 mg 
twice a day orally. Subsequent bronchoscopy after 2 months 
showed residual erythema in the area of the previous biopsy 
without any raised lesion/nodularity (Fig. 2B). Repeated 
bronchoscopy 8 months after initial bronchoscopy showed 
complete resolution with normal mucosa and no erythema. 
CT scan of the chest with contrast done at the time revealed 
no evidence of recurrent disease. Patient discontinued cele-
coxib 2 months after the second bronchoscopy, completing a 
12-month course of treatment.
DISCUSSION
IMT is a rare entity that is composed of myofibroblastic prolif-
eration interposed with inflammatory cell infiltrate that affects 
multiple organs including the lungs. In approximately 70–80% 
of cases affecting the lung, it is clinically asymptomatic, whereas 
in others, it usually presents with cough, hemoptysis, or as a sol-
itary pulmonary nodule.2 A recent study found that IMTs har-
bor, in addition to ALK rearrangement, other rearrangements in 
kinase genes, such as ROS1 and PDGFRβ.3 Cyclooxygenase-2 
enzyme and vascular endothelial growth factor expression in 
IMTs contribute to their growth, rationalizing the use of Non-
steroidal anti-inflammatory drugs, which can induce tumor 
regression through disruption of the vascular endothelial 
growth factor signaling pathway.4 Although surgical resection 
is generally reserved for tumors that are localized, unresectable 
IMTs have been successfully treated with steroids, NSAIDs and 
ALK-inhibitors, such as crizotinib,5 which was not an option in 
the absence of identifiable ALK or ROS1 gene rearrangements. 
In our patient, the NSAID celecoxib proved beneficial in the 
management of local recurrence as an alternate to high-risk sur-
gery, such as pneumonectomy. Case studies on NSAID therapy 
in IMT’s are scarce but have a common inference that NSAID’s 
induce durable remissions and responses persist after ceasing 
therapy with the longest reported response being 4 years in a 
patient with pancreatic head IMT. NSAID therapy should be 
entertained as an alternative for treating unresectable or recur-
rent IMT. Our patient achieved an excellent response to cele-
coxib for a locally recurrent IMT, thus avoiding the morbidity 
of a major surgery. She continues to be clinically asymptomatic 
2 months after ceasing celecoxib administration. Surveillance 
bronchoscopy will be performed within the first 6 months after 
discontinuation of celecoxib.
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FIGURE 2. A, Nodular recurrence (biopsy con-
firmed) on initial surveillance bronchoscopy. B, 
Residual erythema postcelecoxib treatment with no 
pathological evidence of recurrence.
FIGURE 1. A, Atypical spindle 
cells and inflammatory infiltrate 
(H&E stain); 200× magnification. B, 
Negative ALK immunohistochemical 
expression.
